Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1953278 | 0.91 | — | — | |
| SCHEMBL1954615 | 0.88 | CTSS (0.32) | CTSS | |
| SCHEMBL874861 | 0.87 | CTSS (0.36) | NPC1RAB9ACTSS | |
| SCHEMBL1952055 | 0.82 | — | — | |
| SCHEMBL12549142 | 0.80 | TYK2 (0.32) | — | |
| SCHEMBL996629 | 0.79 | ALDH1A1 (0.33) | NPC1RAB9ACTSS | |
| SCHEMBL1954277 | 0.78 | TRPV1 (0.33) | NPC1RAB9A | |
| SCHEMBL7944203 | 0.77 | CTSS (0.40) | NPC1RAB9ACTSS | |
| SCHEMBL883446 | 0.76 | MAPT (0.38) | NPC1RAB9ACTSS | |
| SCHEMBL13336763 | 0.75 | CTSS (0.37) | NPC1RAB9ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927484-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927484-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927484-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20110135599-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135599-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135599-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135599-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, HAVCR2 | NPC1 210/4885RAB9A 1720/4885CTSS 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.